The Case with Type 2 Diabetes Mellitus Regulated by Use of Metformin+Detemir

Abstract views: 53 / PDF downloads: 34


  • Mehmet Keskin Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD
  • Yılmaz Kör Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD.
  • İbrahim Pekmez Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD.
  • Orhan Kılıç Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD.
  • Elif Güler Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD
  • Özlem Keskin Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD
  • Ayşe Balat Gaziantep Üniversitesi Tıp Fakültesi, Çocuk Sağlığı ve Hastalıkları AD.



Adolescent, Type 2 diabetes, Metformin, Insulin detemir


The prevalence of obesity and type 2 diabetes mellitus in adolescent is increased recently related with dietary factors. Early and late decreased insulin release, peripheral insulin resistance and increased hepatic glucose production are responsible for etiopathogenesis of type 2 diabetes mellitus. Obesity is most important risk factor for developing insulin resistance and type 2 diabetes mellitus. Metformin is available oral antidiabetic drug. The long-acting basal analogue insulin detemir is usable for type 1 and type 2 diabetes. This presention showed that metformin with insulin detemir was effective for good glycemic control.


Metrics Loading ...


Fagot-Campagna A. Type 2 diabetes among North- American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr. 2000;136:664-672.

Crawford PB, Story M, Wang MC, Ritchie LD, Sabry ZI. Ethnic issues in the epidemiology of childhood obesity. Pediatr Clin North Am. 2001;48:855-878.

Young TK. Childhood obesity in a population at high risk for type 2 diabetes. J Pediatr. 2000;136:365-369.

Uçkun A, Teziç T, Fırat S, Sipahi T. Impaired glucose tolerance and type 2 diabetes in Turkish children: is obesity really a risk factor? Pediatric Res. 2002;51:124.

Kaufman FR. Obesity and type 2 diabetes in children and young people. Curr Opin Endocrinol Diabetes. 2006;13:332-337.

Uçkun A, Çalıkoğlu AS. Çocukluk çağında tip 2 diyabet. STED. 2003;12:174-179.

Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized, placebo controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006;106:241-246.

Bo S, Cavallo-Perin P, Gentile L. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol. 2000;37:125-129.

Nathan DM, Buse JB, Davidson MB. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-1972.

Sellers EA, Moore K, Dean HJ. Clinical management of type 2 diabetes in indigenous youth. Pediatr Clin North Am. 2009;56:1441-59.

Quarry-Horn JL, Evans BJ, Kerrigan JR. Type 2 diabetes mellitus in youth. J Sch Nurs. 2003;19:195-203.

Phillips PJ. Children get type 2 diabetes too. Australian Family Physician. 2009;38:699-703.

Weiss R, Taksali SE, Tamborlane WV. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care. 2005;28:902-909.

Cruz ML, Bergman RN, Goran MI. Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a positive family history of type 2 diabetes. Diabetes Care. 2002;25:1631-1636.

Arslanian S, Suprasongsin C. Differences in the in vivo insulin secretion and sensitivity in healthy black vs white adolescents. J Pediatr. 1996;129:440-443.

Caprio S. Insulin resistance in childhood obesity. J Pediatr Endocrinol Metab. 2002;15:487-492.

Katzmarzyk PT, Srinivasan SR, Chen W. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics. 2004;114:198-205.

McCance D, Pettitt D, Hanson R. Birth weight and non insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? Br Med J. 1994;308:942-945.

Tang W, Hong Y, Province MA. Familial clustering for features of the metabolic syndrome: the National Heart, Lung and Blood Institute Family Heart Study. Diabetes Care. 2006;29:631-636.

Legro RE, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165- 169.

American Diabetes Association. Type 2 diabetes in children and adolescents. Consensus Statement, Diabetes Care. 2000;23:381-389.

Silverstein J, Klingensmith G, Copeland K. Care of children and adolescents with type 1 diabetes mellitus: a statement of the American Diabetes Association. Diabetes Care. 2005;28:186-212.

Otto-Buczkowska E, Nowowiejska B, Jarosz-Chobot P, Stanczyk J. Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents? Przegl Lek. 2009;66:388-93.

Harden KA, Cowan PA, Velasquez-Mieyer P, Patton SB. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents. J Am Acad Nurse Pract. 2007;19:368-77.

Philips JC, Scheen A. Insulin detemir in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag. 2006;2:277-283.

Demssie YN, Younis N, Soran H. The role of insulin detemir in overweight type 2 diabetes management. Vasc Health Risk Manag. 2009;5:553-560




How to Cite

Keskin, M., Kör, Y., Pekmez, İbrahim, Kılıç, O., Güler, E., Keskin, Özlem, & Balat, A. (2010). The Case with Type 2 Diabetes Mellitus Regulated by Use of Metformin+Detemir. European Journal of Therapeutics, 16(2), 46–49.



Case Reports